Floatz logo

Botensilimab

Colorectal Cancer

National Cancer Institute (NCI)monoclonal_antibodyPhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
59/ 100

Competitive context

713 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Marble Dust
James Varani
Phase 2/3BB
Orectalip
Sinphar Pharmaceutical Co., Ltd
Phase 4BB
Fluorouracilum
UNICANCER
Phase 4BB
Levofolinic Acid
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Botensilimab is also rated in:

colorectal adenocarcinomaActive
BB
Indicative · Phase 2
66 / 100
View asset →
colorectal carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
rectal cancerActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →